Abstract: The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising: a) a safe and effective amount of a vitamin B6 compound selected from the group consisting of pyridoxine, esters of pyridoxine, amines of pyridoxine, salts of pyridoxine and derivatives thereof, including pyridoxamine, pyridoxal, pyridoxal phosphate, and pyridoxic acid; b) a safe and effective amount of a skin care active selected from the group consisting of peptides, phytosterol, sugar amines, their derivatives, and combinations thereof; and c) a dermatologically acceptable carrier for the pyridoxine and the skin care active.

Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva]2-Ciclosporin, in “microemulsion pre-concentrate” and microemulsion form. The compositions typically comprise (1.1) a C1-5alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Abstract: The present invention relates to leave-on compositions for personal care comprising trimethylsilylalkylsilsesquioxanes, particularly trimethylsilyl-n-octylsilsesquioxanes (Caprylyl Trimethicones). Said trimethylsilylalkylsilsesquioxanes are especially useful in formulating emulsions.

Abstract: An emulsion having one oily outer phase, and two aqueous inner phases, one of which is a gel. The emulsion may be used for cosmetic, pharmaceutical, veterinary and detergent purposes.

Abstract: Preparations with deodorizing action are provided. The preparations include the zinc salt of ricinoleic acid; amino-functional amino acids; solubility promoters; organic and/or inorganic acids; and, optionally, water.

Abstract: A topical composition containing one oily outer phase and two aqueous inner phases, one of which is a gel and a process for its preparation. In a preferred embodiment, the topical composition is a sunscreen emulsion containing one or more sunscreen filter substances.

Abstract: There is provided a composition. The cosmetic composition has the following: one or more particulates; a neutralized, carboxylic acid polymer selected from the group consisting of a carbomer, acrylates/C10-30 alkyl acrylate crosspolymer, and any combination thereof; an amount of a polyoxyethylene/polyoxypropylene block copolymer effective to stabilize and maintain dispersion of the one or more particulates; and about 10 wt % to about 90 wt % water. There is also provided a method for making a sunscreen composition. There is also provided a method of stabilizing and maintaining dispersion of particulates in a cosmetic composition.

Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

Abstract: What is described herein is an antiperspirant composition including an active antiperspirant ingredient, and a phenylethyl, benzyl or substituted benzyl ester as additive therein, which is an aryl carboxylic ester of 2-phenylethyl alcohol, 1-phenylethyl alcohol or benzyl alcohol, which leaves a reduced visible white chalky residue on the skin of the user.

Abstract: This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another aspect, this invention provides a pharmaceutical composition for enteral or parenteral administration comprising a macrolide and an acid.

Abstract: The invention is a clear, elastomer-free, gel composition comprising: (a) 14–30 weight % of an antiperspirant active having a low metal to chloride ratio; (b) 7–23.3 weight % of one or more cyclomethicones having a flash point of 100 degrees C. or less; (c) 0.6–0.9 weight % of a silicone surfactant having an HLB value?8; (d) 30–70 weight % water; (e) 3.85–10 weight % of a water soluble glycol or polyglycol and (f) 0.1–3.0 weight % of a non-siliconized organic fragrance solubilizer; wherein the composition is a gel having a viscosity greater than 150,000 centipoise and a ratio of oil phase to water phase in the range of 10:90 to 24:76.

Abstract: Methods and devices for enhanced ultrasound detection based upon changing temperature and ultrasound reflectivity of a temperature-dependent contrast agent bound to an ultrasound target are disclosed. The methods and devices can be used for enhanced imaging alone or in conjunction with drug delivery, with therapeutic approaches such as hyperthermia or cryotherapy or with other imaging modalities.

Abstract: A cosmetic water-in-oil composition is provided which includes a water-in-oil emulsifying silicone surfactant, crosslinked silicone elastomer and conjugated linoleic acid. The conjugated linoleic acid functions to improve radiance on facial surfaces to which the composition is topically applied.

Abstract: A cosmetic water-in-oil composition is provided which includes a water-in-oil emulsifying silicone surfactant, an ultrafine titanium dioxide and conjugated linoleic acid. The presence of conjugated linoleic acid stabilizes the composition against color degradation and also maintains an approximately steady viscosity.

Abstract: A cosmetic water-in-oil composition is provided which includes a water-in-oil emulsifying silicone surfactant, organic sunscreen agent and conjugated linoleic acid. The conjugated linoleic acid functions to moderate shine on facial surfaces to which the organic sunscreen agent formulated composition is topically applied.

Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.

Abstract: A lotion includes a micro-emulsion composition, which is liquid at room temperature and undergoes a phase change to a semi-solid or solid upon contact with a substrate. The micro-emulsion composition can include a polar emollient, a non-polar emollient, a non-ionic surfactant, and a co-surfactant. The invention also includes a substrate treated with the lotion.

Abstract: Propofol solubilised in aqueous micellar preparations of poloxamers is stable at low concentrations and that such preparations are effective administration forms for Propofol.

Abstract: Disclosed is a fluid cosmetic composition comprising a sebum-absorbing calcium silicate. These cosmetic compositions provide effective, long-lasting facial cosmetic coverage that is highly resistant to the sebum-caused deterioration that results in the discoloration and fading typically experienced by conventional cosmetic compositions after a sustained period of use. The cosmetic composition may be in the form of a créme, lotion, gel, semi-solid, dispersion, suspension, foam, mousse or spray.

Abstract: The preparation of novel microemulsions to be used as precursors for solid nanoparticles is described. The microemulsion precursors consist of either alcohol-in-fluorocarbon microemulsions, liquid hydrocarbon-in-fluorocarbon microemulsions, or liquid hydrocarbon-in-water microemulsions. The formed solid nanoparticles have diameters below 200 nanometers and can be made to entrap various materials including drugs, magnets, and sensors. The solid nanoparticles can be made to target different cells in the body by the inclusion of a cell-specific targeting ligand. Methods of preparing the novel microemulsion precursors and methods to cure solid nanoparticles are provided.

Abstract: A composition, comprising, in a physiologically acceptable medium, an aqueous phase dispersed in an oily phase by means of an emulsifier of at least one oligomer or one polymer derived from a polyolefin, comprising a polyolefinic apolar component comprising at least 40 carbon atoms and at least one polar component.

Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

Abstract: The present invention relates to polyoxyethylene-polyoxypropylene (POE-POP) vitamin E, which is prepared from vitamin E by polyethoxylation and polypropoxylation, and a method for preparing the same. The POE-POP vitamin E has a high surface activity and an excellent safety for the skin, so that the POE-POP vitamin E can be advantageously used in the cosmetic industry, the food industry and the medical industry.

Abstract: Water-in-oil emulsions comprising at least one cationic polymer, at least one surface active substance and a content of water and optional water-soluble substances totalling at least 80% based on the total weight of the emulsions.

Abstract: The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.

Abstract: A sunscreen composition which includes at least one UV-B active ingredient therein, optionally with a UV-A active, and a phenylethyl or benzyl ester in an amount sufficient to boost the SPF rating of the UV-B active therein.

Abstract: A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monoglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied between 4 and 22.

Abstract: A formulation, for example an oil-in-water emulsion, comprising an amphoteric surfactant, alkoxylated cetyl alcohol and a polar drug. The drug may be sodium cromoglycate or nedocromil sodium. The formulation may be useful in the treatment of skin disease such as atopic dermatitis.

Abstract: A method for producing a colored cosmetic composition having inorganic pigments resistant to agglomeration in an oil-in-water emulsion. The method includes the following: preparing an oil dispersion by adding inorganic pigments directly to an oil; preparing an aqueous base that includes water; combining the oil dispersion and aqueous base; and partitioning the inorganic pigments between the oil and the aqueous phase under controlled conditions, for example, hydrophile-lipophile balance, agitation time and speed, and cooling rate. The present invention provides a process to easily disperse iron-oxide pigments, even black iron-oxide pigments, in oil-in-water emulsions. The present invention provides colored cosmetic compositions that have excellent properties, such as smoothness, adhesion to skin, uniform color, ease of removal, smudge resistance and non-oiliness.

Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.

Abstract: A description is given of the use of a nanodispersion, which comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (?) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (?) adding the liquid obtained in step (?) to the water phase of the pharmaceutical end formulations, steps (?) and (?) being carried out without any additional supply of energy. The nanodispersions used according to this invention are suitable as transport vehicles for pharmaceutical active agents.

Abstract: Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

Abstract: Disclosed are electrostatically-sprayable topical compositions, more particularly topical emulsion compositions, and methods of treating the skin by electrostatic application of such compositions. In one aspect the composition comprises an insulating external phase comprising one or more insulating materials and a conductive internal phase comprising one or more conductive materials. The compositions preferably also contain one or more particulate materials to be deposited on the skin, e.g., pigments, inert absorbents and the like.

Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-?-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.

Abstract: Cosmetic, dermatological and pharmaceutical compositions containing quaternary ammonium compounds, particularly for hair-treatment, require low setting points, good solubility and dispersibility in aqueous media and a low flash point. It has now been found that such compositions can be formulated with quaternary ammonium compounds and polyhydric alcohols. The invention provides compositions comprising a) at least one quaternary ammonium compound, b) at least one branched alcohol having 8 to 36 carbon atoms or a mixture of at least one branched alcohol and at least one unbranched alcohol having 8 to 36 carbon atoms, and c) at least one polyhydric alcohol having 2 to 6 carbon atoms. The resulting compositions have a low setting point or melting point, good solubility and dispersibility in aqueous media and a low flash point.

Abstract: A liquid, cold-temperature-stabilized preservative is based on carbendazim or a salt thereof, which includes, as low-temperature stabilizer, at least one aromatic alcohol and/or at least one aromatic glycol ether and/or a pyrrolidone.

Abstract: A rinse-off composition comprising in percent by weight 0.10–10.00 of a dispersion of bismuth oxychloride 3.50–90.00 of a surfactant, 0.001–0.050 of a dye, 3.00–15.00 of an emollient and 10.00–80.00 of water; said dispersion of bismuth oxychloride containing bismuth oxychloride platelet particles having a lateral width of 5–25 microns and a thickness of 20–200 nm, said platelet particles being substantially covered a liquid vehicle and said liquid vehicle being present in an amount sufficient to maintain a stable dispersion and to provide for facile resuspension.

Abstract: A cosmetic, dermopharmaceutical or pharmaceutical composition includes a composition containing an oil phase, an aqueous phase, a water-in-oil (W/O) emulsifier, an oil-in-water (O/W) emulsifier, in the form of a positive latex comprising 20 wt. % to 60 wt. %, and preferably 30 wt. % to 50 wt. %, of a branched or linear anion polyelectrolyte based on 2-methyl 2-[(1-oxo-2-propenyl)amino] 1-propanelsulphonic acid partly or completely salified, copolymerized with acrylamide, the organic solvent constituting the oil phase of the positive latex being isohexadecane.

Abstract: Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs are provided. Also provided are methods for minimizing wastage of drugs administered by nebulizer, and for the achievement of quantitative dosing with diluent from a mass marketed formulations, which because of the mass market is much less costly per dose than formulations manufactured specifically for much lower volume medical use.

Abstract: The invention provides acidic cosmetic, dermatological, and pharmaceutical agents comprising at least one copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) optionally, one or more further olefinically unsaturated, noncationic comonomers, C) optionally, one or more olefinically unsaturated, cationic comonomers, D) optionally, one or more silicon-containing component(s), E) optionally, one or more fluorine-containing component(s), F) optionally, one or more macromonomers, G) the copolymerization taking place if desired in the presence of at least one polymeric additive, H) with the proviso that component A) is copolymerized with at least one component selected from one of the groups D) to G).

Abstract: This invention relates to a composition comprising ubiquinone having superior dispersion-stability in an aqueous solution and high bioavailability. The ubiquinone(s) is dispersed and emulsified in an aqueous solution of a water-soluble material in the presence of an organic acid(s) to form a protective colloid, the average particle size of the suspended particles being not more than 5 ?m. The liquid composition can be adsorbed in or carried on an excipient, or dried.

Abstract: The invention relates to cosmetic, dermatological, and pharmaceutical products containing an electrolyte. The products are obtained by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, and B) optionally, one or more further olefinically unsaturated, noncationic comonomers, C) optionally, one or more olefinically unsaturated, cationic comonomers, D) optionally, one or more silicon-containing component(s), E) optionally, one or more fluorine-containing component(s), F) optionally, one or more macromonomers, G) optionally, the copolymerization taking place in the presence of at least one polymeric additive, H) with the proviso that component A) is copolymerized with at least one component selected from one of the groups D) to G).

Abstract: Anti-plaque emulsions and methods of use are provided. The emulsion comprises a surfactant, emulsifier, and triclosan.

Abstract: The invention relates to an aqueous colloidal dispersion of a compound of cerium and at least one other element M chosen from among the rare earths other than cerium; titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, aluminium, gallium and zirconium. This dispersion is characterized in that it displays a conductivity of at most 5 mS/cm. It is obtained by a process in which there is reacted with a base a mixture of at least one salt of cerium with at least one salt of an element M mentioned above and in the presence of an acid in a quantity such that the atomic ratio H+/(Ce+M) is greater than 0.1, then the precipitate from the preceding reaction is re-dispersed in water. The dispersions of this type cane be used in catalysis, in lubrication, in ceramics, in the manufacture of luminophorous compounds, in cosmetics and as anticorrosion agents.

Abstract: This invention relates to new dermocosmetic and pharmaceutical compositions which are useful for improving and treating hyperreactive skin conditions and more generally allergic-type reactions and/or intolerance phenomena, whether they are caused by external factors or factors intrinsic to the individual. The compositions of this invention preferably contain an anti-radical, in anti-inflammatory and an anti-allergic activity for the treatment of sensitive and/or allergic skin.

Abstract: A composition for treatment of pollution comprises a first component comprising a carbon containing substance in an oil phase and a second component comprising a nutrient in a water phase, the second component being formed as an emulsion within the first component. A third component comprising a diluent is added to the first and second components.

Abstract: Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.

Abstract: A W/O/W type composite emulsion, wherein a W/O type emulsion containing water, an oil ingredient and a lipophilic emulsifier each in a proportion expressed in term of mass ratio falling within a range enclosed with bold lines in FIG. 1 is dispersed in an external aqueous phase with a water-soluble macromolecule blended therein has a sufficient stability, and permits preserving a percent inclusion of medical substances included in an internal aqueous phase of the W/O/W type composite emulsion at a high level. Because of the characteristics, it is now possible to blend in a liquid formulation medical substances having an unfavorable taste or unstable medical substances which have to date hardly been included in liquid formulations with low viscosity, so that the W/O/W type composite emulsion can be utilized for liquid formulations including a liquid formulation for internal application, injections, etc.

Abstract: Pharmaceutical dosage forms for anticancer drugs, and paclitaxel in particular, are described in which the active drug is formulated as storage stable self-emulsifying preconcentrate.

Abstract: The present invention provides emollient creams composed of sulfur, sodium sulfacetamide and a botanically-derived anti-inflammatory ingredient. The creams are alcohol-free and have a pH at or above 7.0.